Inventor · disambiguated record
Luc Desnoyers
Also filed as: DESNOYERS LUC · DESNOYERS LUC ROLAND · FILVAROFF ELLEN · GODOWSKI PAUL J
143 granted patents·503 pending applications·1,498 citations·filing 2001–2024
99Inventor score
Top patents by PatentIndex Score
646 records- 0198US10533053B2Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptorCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 14, 2020·12 cites·20 claims
- 0298US10179817B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 15, 2019·36 cites·58 claims
- 0398US9540440B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2014·Granted Jan 10, 2017·31 cites·25 claims
- 0498US6635468B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Oct 21, 2003·92 cites·15 claims
- 0597US10745481B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·22 cites·88 claims
- 0697US10709799B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·10 cites·31 claims
- 0797US9889211B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Feb 13, 2018·29 cites·52 claims
- 0897US9120853B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 1, 2015·52 cites·43 claims
- 0997US7026448B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Apr 11, 2006·35 cites·12 claims
- 1097US6936436B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Aug 30, 2005·37 cites·16 claims
- 1197US6936697B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Aug 30, 2005·37 cites·5 claims
- 1296US9545442B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·19 cites·57 claims
- 1396US6924355B2PRO1343 polypeptidesGENENTECH INC·Filed 2001·Granted Aug 2, 2005·49 cites·11 claims
- 1495US11753466B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·7 cites·64 claims
- 1595US11180562B2Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodiesCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 23, 2021·5 cites·22 claims
- 1695US10233244B2Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Mar 19, 2019·26 cites·48 claims
- 1795US9737623B2Antibodies that bind activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2014·Granted Aug 22, 2017·19 cites·21 claims
- 1895US7125962B2Anti-Pro268 antibodiesGENENTECH INC·Filed 2002·Granted Oct 24, 2006·13 cites·5 claims
- 1994US11267896B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Mar 8, 2022·10 cites·34 claims
- 2094US9517276B2Compositions and methods for conjugating activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2014·Granted Dec 13, 2016·24 cites·31 claims
- 2194US7696319B2PRO1772 antibodiesGENENTECH INC·Filed 2002·Granted Apr 13, 2010·12 cites·5 claims
- 2294US7112656B2PRO1312 polypeptidesGENENTECH INC·Filed 2001·Granted Sep 26, 2006·31 cites·7 claims
- 2394US7074592B2Secreted and transmembrane polypeptides nucleic acid encodingGENENTECH INC·Filed 2001·Granted Jul 11, 2006·29 cites·8 claims
- 2494US6828146B2Nucleic acid encoding PRO229 polypeptidesGENENTECH INC·Filed 2001·Granted Dec 7, 2004·19 cites·9 claims
- 2593US11890354B2Activatable antibodies that bind epidermal growth factor receptor and methods thereofCYTOMX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·2 cites·16 claims
- 2693US10568977B2Antibodies that bind activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted Feb 25, 2020·8 cites·20 claims
- 2793US7705195B2Screening methodGENENTECH INC·Filed 2003·Granted Apr 27, 2010·47 cites·34 claims
- 2893US7678373B2Anti-FGF19 antibodies and methods using sameGENENTECH INC·Filed 2007·Granted Mar 16, 2010·20 cites·21 claims
- 2993US7390879B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2002·Granted Jun 24, 2008·36 cites·6 claims
- 3093US7034136B2Nucleic acids encoding PRO1159 polypeptidesGENENTECH INC·Filed 2001·Granted Apr 25, 2006·26 cites·13 claims
- 3193US6974689B1Nucleic acid encoding PRO211 polypeptidesGENENTECH INC·Filed 2001·Granted Dec 13, 2005·27 cites·8 claims
- 3293US6972185B2Nucleic acids encoding PRO844 polypeptidesGENENTECH INC·Filed 2001·Granted Dec 6, 2005·25 cites·15 claims
- 3393US6723535B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Apr 20, 2004·14 cites·17 claims
- 3493US6686451B1Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Feb 3, 2004·23 cites·5 claims
- 3592US12139543B2Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFRCYTOMX THERAPEUTICS INC·Filed 2021·Granted Nov 12, 2024·1 cites·25 claims
- 3692US7094567B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Aug 22, 2006·12 cites·10 claims
- 3792US7029874B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Apr 18, 2006·25 cites·20 claims
- 3892US6956108B2PRO1184 antibodiesGENENTECH INC·Filed 2001·Granted Oct 18, 2005·20 cites·4 claims
- 3992US6953836B2PRO844 polypeptidesGENENTECH INC·Filed 2001·Granted Oct 11, 2005·21 cites·11 claims
- 4092US6930170B2PRO1184 polypeptidesGENENTECH INC·Filed 2001·Granted Aug 16, 2005·21 cites·11 claims
- 4191US7208312B1Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2003·Granted Apr 24, 2007·44 cites·6 claims
- 4291US7169912B2PRO1017 nucleic acidsGENENTECH INC·Filed 2001·Granted Jan 30, 2007·14 cites·15 claims
- 4391US7034122B2Antibodies to PRO1159 polypeptidesGENENTECH INC·Filed 2001·Granted Apr 25, 2006·17 cites·4 claims
- 4491US7033786B2Pro1340 nucleic acidsGENENTECH INC·Filed 2001·Granted Apr 25, 2006·9 cites·16 claims
- 4591US7033785B2PRO1347 nucleic acidsGENENTECH INC·Filed 2001·Granted Apr 25, 2006·9 cites·15 claims
- 4691US7029873B2Nucleic acids to PRO1387 polypeptidesGENENTECH INC·Filed 2001·Granted Apr 18, 2006·18 cites·15 claims
- 4791US7019116B2PRO 1387 polypeptidesGENENTECH INC·Filed 2001·Granted Mar 28, 2006·19 cites·12 claims
- 4891US6806352B2Secreted and transmembrane polypeptides and nucleic acids encoding the sameGENENTECH INC·Filed 2001·Granted Oct 19, 2004·41 cites·12 claims
- 4991US2025215094A1Method of using an anti-epidermal growth factor receptor (egfr) activatable antibody to detect the presence or absence of a cleaving agent and egfrCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5090US12502439B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Dec 23, 2025·0 cites·20 claims
Showing the top 50 of 646 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →